Dr Rabia T Khan - Deep Science Ventures
Rabia Khan trained as an immuno-geneticist with a passion for bridging the worlds of science, business and technology. Following on from her PhD, she joined Meta, an AI company using NLP to uncover knowledge within the biomedical literature. In her role as VP Commercial Partnerships, she worked with the CEO to understand product-market fit, built products for commercial partners and was instrumental in the IAPRA partnership. Meta has since been acquired by Chan Zuckerberg BioHub.
Following Meta, she went on to a post-doctoral fellowship at the Francis Crick Institute under Dr. Frickel, where she worked on stem-cell models of the immune response to infection. After a short post-doc, Rabia returned to the tech world and joined BenevolentAI, an AI-enabled drug discovery company, as a scientist and established a number of pre-clinical drug-discovery programs, leading the Glioblastoma program and the Macular Degeneration partnership. She worked closely with the BAI product team to define product vision based on drug-discovery needs. More recently, she worked closely with Prof. Jackie Hunter in her role as Associate Director, Strategy and Planning.
She recently left her role at BAI to establish her own venture in computational drug discovery as a founder at Deep Science Ventures.